Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

Products in Development

Sunesis Products In Development

QINPREZO™ (vosaroxin)
Vosaroxin is an anti-cancer quinolone derivative, or AQD - a class of compounds that has not been used previously for the treatment of cancer.

TAK-580 (RAF)
TAK-580 (formerly called MLN2480) is an oral pan-Raf kinase inhibitor with a distinct molecular signature which has exhibited a promising preclinical profile.

SNS-062 (BTK)
SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK).

PDK1 Inhibitor Program)
In January 2014, we in-licensed a series of selective oral 3-phosphoinositide dependent protein kinase 1 (PDK1) inhibitors from Millennium that were discovered under a research collaboration agreement between Biogen Idec and Sunesis.

Presentations & Publications
We strongly believe that sharing ideas and advances with other scientists helps move the oncology treatment discipline forward. Sunesis scientists and leaders regularly present hypotheses and findings at conferences and symposia worldwide.